Abstract: Disclosed is a compound with a structure as shown in Formula (101) and a corresponding drug conjugate, wherein the drug conjugate can be specifically targeted at cells and has a low toxicity and an excellent delivery efficiency.

Abstract: There is described a cascade-type compact hybrid energy cell (CHEC) that is capable of individually and concurrently harvesting solar, strain and thermal energies. The cell comprises an n-p homojunction nanowire (NW)-based piezoelectric nanogenerator and a nanocrystalline/amorphous-Si:H single junction cell. Under optical illumination of ˜10 mW/cm2 and mechanical vibration of 3 m/s2 at 3 Hz frequency, the output current and voltage from a single 1.0 cm2-sized CHEC was found to be 280 ?A and 3.0 V, respectively—this is are sufficient to drive low-power commercial electronics. Six such CHECs connected in series were found to generate enough electrical power to light emitting diodes or drive a wireless strain gauge sensor node.

Abstract: There is described a cascade-type compact hybrid energy cell (CHEC) that is capable of individually and concurrently harvesting solar, strain and thermal energies. The cell comprises an n-p homojunction nanowire (NW)-based piezoelectric nanogenerator and a nanocrystalline/amorphous-Si:H single junction cell. Under optical illumination of ˜10 mW/cm2 and mechanical vibration of 3 m/s2 at 3 Hz frequency, the output current and voltage from a single 1.0 cm2-sized CHEC was found to be 280 ?A and 3.0 V, respectively—this is are sufficient to drive low-power commercial electronics. Six such CHECs connected in series were found to generate enough electrical power to light emitting diodes or drive a wireless strain gauge sensor node.

Abstract: The present invention relates to the compounds of the formulae (I) and (I-1) and the process for preparing the same, uses of the compounds for the treatment of diseases associated with platelet aggregation and in the manufacture of a medicament for the treatment of diseases associated with platelet aggregation, and relates to a pharmaceutical composition and a pharmaceutical formulation containing the compounds, wherein the definitions of R1, R2, R3 and R2a in the formulae are the same as those in the description.

Abstract: The present invention relates to the compounds of the formulae (I) and (I-1) and the process for preparing the same, uses of the compounds for the treatment of diseases associated with platelet aggregation and in the manufacture of a medicament for the treatment of diseases associated with platelet aggregation, and relates to a pharmaceutical composition and a pharmaceutical formulation containing the compounds, wherein the definitions of R1, R2, R3 and R2a in the formulae are the same as those in the description.

Abstract: The present invention relates to the compounds of the formulae (I) and (I-1) and the process for preparing the same, uses of the compounds for the treatment of diseases associated with platelet aggregation and in the manufacture of a medicament for the treatment of diseases associated with platelet aggregation, and relates to a pharmaceutical composition and a pharmaceutical formulation containing the compounds, wherein the definitions of R1, R2, R3 and R2a in the formulae are the same as those in the description.